

Atesos medical AG

Article 33(1) DECLARATION OF REACH COMPLIANCE

REACH¹ Article 33(1) - Communication on Substances of Very High Concern in Products

REACH Candidate List version Date*	14/06/2023			
*REACH Candidate list of Substances of Very High Concern for Authorisation including all				
substances included as of the date indicated.				

To whom it may concern,

We hereby send you information related to the REACH regulation (Regulation (EC) No. 1907/2006). In accordance with Article 33(1) of the REACH regulation, this communication applies to all Products sold or otherwise placed on the market by **Atesos medical AG** prior to the signature date shown below.

If no such Products contain Substance(s) of Very High Concern ("SVHCs")² over the threshold level, this option must be selected:

Checking this box certifies that none of the Products referenced above contain SVHC(s), as per the list version dated above, at a concentration over the threshold of 0.1% weight by weight at the article level.

OR, if any such Products contain Substance(s) of Very High Concern ("SVHCs") over the threshold level, the table below must be completed. Each Product referenced in the table below is deemed to contain one or more of the below-referenced SVHC(s), as per the list version dated above, at a concentration over the threshold of 0.1% weight by weight at the article level. Products not listed do not contain listed substances over that threshold.

REACH SVHC Candidate List Status and Information for Articles with SVHCs Over Threshold

Product(s)	Substance % Present (w/w)	Substance name	CAS Number	Safe use information (if applicable)

¹<u>Regulation (EC) No 1907/2006 of the European Parliament and of the Council, dated 18 December 2006</u>, concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals.

² <u>REACH candidate list substance meeting the criteria in Article 57 and identified in accordance with Article 59(1) of the REACH regulation.</u>

Limitations

Atesos medical AG believes that the information provided herein is accurate. The provided information is based upon data obtained from ongoing due diligence concerning goods and materials provided by third party suppliers. Atesos medical AG provides such information "AS IS", without any express or implied warranty of any kind. Atesos medical AG reserves the right to update and modify this communication, as it believes necessary or appropriate.

Please do not hesitate to ask for further information.

Print Name:	Mirjam Ermel	Signed:	Q. Carl
Title:	Quality Manager	Date:	01.07.2023
Email:	mirjam.ermel@atesos.ch	Phone:	+41 (0)62 823 15 49
Address:	Schachenallee 29		
(cont'd)	CH-5000 Aarau		